- Global Pharma News & Resources

MedVector Launches its Prime-Control Technology to Expand Subject Enrollment Beyond Clinical Trial Sites

Unlocking Access to Millions of Clinical Trial Subjects Will Help CROs and Sponsors Fill Studies Faster

March 25, 2021 - MedVector has begun the rollout of its Prime-Controltm Technology, to give contract research organizations (CROs) and pharma sponsors access to patients without triggering new clinical trial sites.

 MedVector is the only company that partners with CROs, sponsors, and patient recruitment companies to expand subject participation beyond existing clinical trial sites.

Clinical trials often hit roadblocks when they lack access to qualified subjects. MedVector’s Prime-Control Technology unlocks access to patients trapped behind point-of-care providers, non-participating physicians, and high-end specialists, including those found near inner-city hospitals and in rural communities. This new technology will significantly accelerate clinical trials by reducing delays in subject enrollment and directing more volume to existing, traditional sites.  MedVector reduces the number of necessary sites, thus, reducing risk, while improving data quality and bringing new medications to market more quickly.

“Our system now gives CROs and patient recruitment companies access to the vast majority of patients qualified to participate in clinical trials without triggering new sites,” says MedVector Co-Founder and Chief Executive Officer Scott Stout. “Non-participating hospitals and private practices are afraid to lose patients, so they are reluctant to refer them to other locations. MedVector’s Prime-Control Technology enables principal investigators [PIs] to virtually monitor subjects face to face, while subjects remain at their local provider’s office, which eliminates the lost patient issue.”

Turnkey Trial Visits

Prior to an appointment, MedVector ships a shoebox-sized device to the subject’s local healthcare provider. The plug and play unit automatically connects to the appropriate clinical trial site, and the PI controls the entire live session as if the PI and subject are in the same room.

At the subject’s location, the local nurse assists the PI -- drawing blood, measuring vital signs, and performing other generic procedures under the “supervision” and “delegated authority” of the PI. The PI enters all clinical data, adhering precisely to the same protocols for all appointments, and maintaining the same good clinical practice (GCP) as a traditional clinical trial appointment.

Before MedVector, PIs were confined to specific geographic footprints. Now, PIs can continue to monitor subjects the traditional way, while increasing volumes by also monitoring subjects virtually, the MedVector way.

“It is widely known that slow enrollment causes delays in nearly 80% of clinical trials, and many subjects drop out because of travel time and other inconveniences,” says MedVector Co-Founder and Senior Vice President of Medical Affairs Dr. Dennis J. Patterson. “Patients are more comfortable participating in trials when their own physician is involved.”

Incorporating MedVector into existing trials also enables CROs to reach and enroll a more geographically and socioeconomically diverse population. With MedVector, no patient is too far away or left behind.

About MedVector

MedVector has developed a clinical trial subject-portal that expands participation beyond existing clinical trial sites giving CROs access to millions of diverse subjects without triggering new sites. MedVector's Prime-Control technology extends the reach of PIs to include patients at non-participating physician’s offices, and those who reside in inner cities and rural communities. The proprietary platform works within current protocols and enables Pharma Sponsors to bring medications to market more quickly. With MedVector, no patient is too far away, or left behind. MedVector is headquartered in El Segundo, California. For more information, visit us at  

Editor Details

  • Name:
    • Andrew Lavin
Last Updated: 25-Mar-2021